PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Candidiasis, Oral”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1979

Sensitivity of Candida albicans from patients with chronic oral candidiasis.

Many patients with oral candidiasis respond very slowly or not at all to therapy with amphotericin. Strains of Candida albicans were collected from 17 patients clinically resistant and from 15 who responded to a normal course of amphotericin treatment. Minimal inhibitory concentrations (MIC) determined on diagnostic sensitivity test agar plates gave values of: amphotericin 0-5 mg/l; nystatin 50 i.u./ml; chlorhexidine 12.5 mg/l. No clear MIC could be determined with plates containing miconazole. No difference was noted in MIC values between the 2 groups of patients. Tube-dilution tests in Sabouraud's broth gave MIC values of: amphotericin 0.25 mg/l; nystatin 12.5 i.u./ml; chlorhexidine 1.5 mg/l; miconazole 8-32 mg/l; ketonazole 64 mg/l. Persistence of oral candidiasis is not an indication of infection with resistant organisms. Despite difficulties in in vitro sensitivity testing of miconazole a clinical trial of the drug for treating oral candidiasis is indicated.

Amphotericin B↗
PubMed1977

Miconazole in oral candidiasis.

Twenty-four patients were treated with oral miconazole (250 mg) for a total of 35 episodes of oral candidiasis. Sixteen had various forms of leukaemia and all were massively predisposed to fungal infection because of granulocytopenia and treatment with prednisolone and antibiotics. Clinical cure was observed in all 35 of the treated episodes, with a mean treatment time of five days, cure being observed in two to three days. When patients violating the protocol were excluded, the mycological cure rate was 97%. In 21 episodes there was a recurrence less than one month after miconazole treatment, probably because of reinfection. No side-effects ascribable to miconazole were observed, even in the severely debilitated patients, and the orally administered drug appeared to be superior to other commercially available antimycotic preparations.

Administration, Oral↗
PubMed1978

Treatment of chronic oral candidiasis with clotrimazole troches. A controlled clinical trial.

Twenty patients with chronic oral candidiasis were assigned by random allocation to a two-week course of either 10-mg clotrimazole buccal troches or placebo taken five times daily in a double-blind clinical trial. Each of the 10 recipients of clotrimazole had marked regression of symptoms and mucosal lesions, and in nine patients potassium hydroxide preparations and cultures of mucosal scrapings gave no evidence of candidiasis. In contrast, only one of the 10 patients receiving placebo showed any improvement. The clinical outcome in the clotrimazole-treated group was significantly more favorable (P less than 0.001) than in the group receiving placebo. No adverse reactions to the drug were observed. After the blind phase of their trial, 15 patients were treated with clotrimazole troches in an open trial. One to three troches per day were found adequate to sustain remissions. We conclude that clotrimazole is highly effective treatment for chronic oral candidiasis.

Adolescent↗
PubMed1976

Clotrimazole troches: a new therapeutic approach to oral candidiasis.

To ascertain the topical effectiveness of clotrimazole in oral candidiasis, a troche form was administered to 12 patients suffering from longstanding infection. One-half of the patients took one 10 mg troche and the other half of the patients one 50 mg troche, ten times a day. The troches were not chewed, but were retained in the mouth until completely dissolved. The impressive clinical and mycological response to this treatment as well as the lack of toxicity strongly indicate that further trials are warranted.

Administration, Topical↗
PubMed1979

Incidence of oral candidiasis during therapy with triamcinolone acetonide aerosol.

During treatment of 63 asthmatic patients for up to 12 months with an investigational drug, triamcinolone acetonide aerosol, no clinically diagnosed oral candidiasis occurred. After 14 months of treatment one patient (1.6%) developed an oral fungal infection. This low incidence prompted a survey concerning the incidence of oral candidal infection in the patients who took part in the entire clinical trial program of triamcinolone acetonide aerosol. The survey revealed a 2.5% occurrence of oral candidiasis among 674 patients who completed at least four weeks of treatment. While direct comparisons were not available, the incidence of oral candidiasis during treatment with triamcinolone acetonide aerosol was lower than that reported for other similarly administered steroid drugs.

Adolescent↗
PubMed1977

Hibitane in the treatment of oral candidiasis.

Denture stomatitis (chronic atrophic candidosis) is a very common complication to the wearing of complete dentures. The infection is due to a contamination of the denture by yeasts. In a number of studies the clinical effect of Hibitane when used as a denture disinfectant has been studied. It was found that Hibitane (0.2--2%) caused a significant amelioration of inflamed palatal tissues and a reduction in the number of yeast cells harbored on the palatal mucosa and the fitting surface of the dentures. However, relapse of the infection was frequent after treatment was sustained. It was concluded that Hibitane could not be recommended for routine denture disinfection, first, because it caused staining of the dentures, second, because of the relative resistance of the yeast to the action of the drug. However, it seems justified to use Hibitane prophylactically as a denture disinfectant in patients who are highly susceptible to developing disseminating or systemic candidosis. Hibitane is a valuable drug in the treatment of denture stomatitis when used as a denture disinfectant.

Biguanides↗
PubMed1978

Oral candidiasis.

Explore the source record for details and available documents.

Candidiasis, Oral↗
PubMed1979

The incidence of oral candidiasis with use of inhaled corticosteroids.

The incidence of thrush occurring among patients receiving inhaled corticosteroids as reported by various investigators is presented. The data were standardized according to diagnostic criteria, duration of treatment and size of patient population. Although proper assessment of the relative risk of thrush incurred with the use of aerosolized corticosteroids must await large-scale randomized, blind, comparative trials, these results of past studies give a general indication of what may be expected.

Administration, Intranasal↗
PubMed2026

In Vitro comparison of herbal and conventional antifungals against Candida strains in Oral candidiasis: A systematic review and meta-analysis.

OBJECTIVE: This study aimed to systematically review and meta-analyze the in vitro antifungal activity of herbal and conventional antifungals against Candida strains. DESIGN: In vitro studies were identified through PubMed, Embase, Scopus, and Web of Science up until May 2026. This review is registered with Prospero (CRD420251128404). Eligibility was determined using the Population, Intervention, Comparison, and Outcome (PICO) framework, with specific inclusion and exclusion criteria focused on in vitro antifungal investigations comparing herbal antifungals with conventional antifungals. The risk of bias was assessed using the modified Quality Assessment Tool for In Vitro Studies (QUIN Tool). A meta-analysis was performed, with the primary outcome measure being the ratio of means (RoM). RESULTS: The systematic review included twenty-five articles. Most studies showed different results in inhibition zones or minimum inhibitory concentrations between herbal and conventional agents. The meta-analysis indicates that certain herbal antifungals are equally effective as or more effective than conventional antifungals against Candida dubliniensis, Candida lusitaniae, and Candida tropicalis. While the efficacy of herbal antifungals for Candida albicans and Candida glabrata was modest, Piper betle L. demonstrated significant inhibitory potential. In contrast, conventional antifungals outperformed herbal antifungals against Candida krusei and Candida parapsilosis. CONCLUSIONS: This systematic review and meta-analysis highlight herbal medicine as a potential antifungal therapy for oral candidiasis, emphasizing the need for new strategies due to resistance to conventional antifungals.

Humans↗
PubMed1978

Refractory oral candidiasis. Report of a case.

A 55-year-old male patient with no significant medical history or systemic physical findings was found, on routine dental examination, to have an oral Candida albicans infection. The condition failed to clear completely after 21 days of nystatin therapy. A 5-day course of clotrimazole was then initiated. Complete clearing of all signs of candida infection occurred in 48 hours, but the infection recurred by the twentieth day of follow-up. A 14-day regimen was then prescribed. Again, the condition cleared in 48 hours, and at the 6-month follow-up all signs of candida involvement, including cultures and smears, remained negative. As no reports of the use of clotrimazole vaginal tablets in oral candidiasis clinically refractory to nystatin therapy were found in the literature of the last 11 years, it was thought that this case was of significant interest.

Administration, Oral↗
PubMed1979

[Oral candidiasis in leukoplakia and carcinoma of the oral cavity (author's transl)].

The incidence of Candida albicans and other candida species were examined by mycological culture and histologically in 193 patients with various forms of oral leukoplakia and 14 patients with carcinoma of the oral mucosa, the results being compared with a control group of 137 subjects with a normal mucosa. Comparing the leukoplakia groups one with the other and with the control group revealed definite, usually statistically significant, differences in the incidence of fungi: 46.4% of patients, 29.2% among controls. The incidence of oral fungi was 35.4% among those with noxigenic leukoplakia, 50% in precancerous leukoplakia, 71.5% in mucosal carcinoma, and 49% in nosogenic leukoplakia (mainly lichen planus mucosae). The fungal elements could be demonstrated histologically much less frequently than by culture, but the difference of demonstration was statistically more significant between the different forms of leukoplakia. It is probable that chronic candidiasis in leukoplakia is not carcinogenic as such but is the microbiological and indicator of a local or systemic disorder of the cellular immune system.

Candida↗
PubMed1979

Double-blind trial comparing two dosage schedules of beclomethasone dipropionate aerosol with a placebo in chronic bronchial asthma. Second report of the Brompton Hospital/Medical Research Council Collaborative Trial.

A follow-up study to 52 weeks is reported on 95 corticosteroid-dependent asthmatics who took part in a double-blind, controlled trial of beclomethasone dipropionate for 28 weeks. During the 28 weeks two dosage schedules (800 microgram and 400 microgram daily) were compared with a placebo. If the corticosteroid tablet dosage had been at least halved and the clinical condition was satisfactory, the allocated regimen was continued 'blind' for the second period (29-52 weeks); 51 patients continued for this period, 46 on beclomethasone dipropionate. If progress was unsatisfactory, known beclomethasone dipropionate 800 microgram daily was substituted, the supervision remaining unchanged, the clinical supervisors remaining unaware which schedule had been received during the first 28 weeks. Nearly all the patients who at least halved their corticosteroid tablet dosage by 28 weeks continued to do well up to 52 weeks on the allocated regimen. When the placebo patients with unsatisfactory progress at 28 weeks were changed to 800 microgram beclomethasone dipropionate they showed a substantial improvement. Patients changed from 400 to 800 microgram showed little improvement on average. Approximately 30% of the whole group of patients failed to have their dosage of corticosteroid tablets, despite receiving 800 microgram beclomethasone dipropionate daily for six or more months. The cumulative incidence of 'oral candidiasis' (as defined for this report) in placebo patients changed at 28 weeks to 800 microgram beclomethasone dipropionate daily was 30% at 36 weeks and 43% at 52 weeks. Of eight patients increased from 400 microgram to 800 microgram daily, one had 'candidiasis' by 36 weeks and three by 52 weeks. Oral candidiasis was often asymptomatic and never led to the discontinuation of the corticosteroid aerosol, although the dosage was reduced in nine of the 30 who received 800 microgram beclomethasone dipropionate during the first 28 weeks. The incidence of bacterial infections in patients on beclomethasone dipropionate was similar to that of the placebo group and systematic laboratory investigations revealed no increase in the rate of isolation of potential pathogens.

Adolescent↗
PubMed1976

[Mucous membrane of the mouth and prostheses in old people (author's transl)].

The majority of people of advanced age at present have either very many gaps in their dentures or they have no teeth at all. For this reason they can only wear broad-base plate-type bridged, which can lead to pathological changes of the mucous membrane. The author uses the complex etiology of prothetic stomatopathy, in which not only changes in the mucous membrane of the mouth associated with ageing but also hormonal changes (menopause), general diseases and oral candidiasis play a role, to illustrated the necessity of collaboration between stomatologists and geriatricians. Oral and prosthetic hygiene degenerates with increasing age. The average period of wearing prostheses also increases with the age and the danger of chronic mucous membrane damage also increases. But since old people seldom if ever consult a stomatologist, every geriatrician should also have a look at the mucous membrane of the mouth when examining old patients.

Age Factors↗
PubMed1979

Inhaled corticosteroid aerosols and candidiasis.

A three-month controlled study was performed to assess the cumulative incidence of oral Candida carriage and thrush in patients starting to take betamethasone valerate aerosol (800 microgram/day) for control of their asthma. Four of 41 patients on the corticosteroid aerosol developed thrush compared with none of 40 in the control group. However, the number of cumulative saliva culture positives for C. albicans rose by a similar amount (approximately 20%) in each group. A simple mouthwash procedure was shown to have no prophylactic benefit in the aerosol group. Oral candidiasis was not, however, clinically important.

Administration, Oral↗
PubMed1979

Clinical evaluation of oral Candida in cancer chemotherapy patients.

No overt clinical oral candidiasis was noted upon either direct oral examination or review of medical records. No significant change in percent of Candida species as compared to other populations is seen in this study. Varying percents of individual species do differ from other reports. Alimentary and digestive tract tumors represented over 56% of the primary malignancies. There was a significant correlation between decrease in salivary pH and increase in percent of Candida species growth. Most significantly, however, the preliminary data in this study might eventually contribute to continuing investigation of Candida species in human cancer patients.

Adolescent↗